Pancreatic cancer subtypes: a roadmap for precision medicine

References

• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
   PubMed Web of Science ®Google Scholar
• Du Y, Zhao B, Liu Z, et al. Molecular subtyping of pancreatic cancer: translating genomics and transcriptomics into the clinic. J Cancer. 2017;8:513–522.
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ, Brody JR. Therapeutic implications of molecular subtyping for pancreatic cancer. Oncology (Williston Park).2017;15:159–166, 168.
   Google Scholar
• Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500–503.
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806.
   PubMed Web of Science ®Google Scholar
• Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168–1178.
   PubMed Web of Science ®Google Scholar
• Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing technologies. Molecular Cell. 2015;58:586–597.
   PubMed Web of Science ®Google Scholar
• Badea L, Herlea V, Dima SO, et al. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008;55:2016–2027.
   PubMedGoogle Scholar
• Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009;16:259–266.
   PubMed Web of Science ®Google Scholar
• Grützmann R, Pilarsky C, Ammerpohl O, et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia. 2004;6:611–622.
   PubMed Web of Science ®Google Scholar
• Balagurunathan Y, Morse DL, Hostetter G, et al. Gene expression profiling based identification of cell surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther. 2008;7:3071–3080.
   PubMed Web of Science ®Google Scholar
• Noll EM, Eisen C, Stenzinger A, et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med. 2016;22:278–287.
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch A, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.
   PubMed Web of Science ®Google Scholar
• Humphris JL, Patch A-M, Nones K, et al. Hypermutation in pancreatic cancer. Gastroenterology. 2017;152:68–74.e2.
   PubMed Web of Science ®Google Scholar
• Schlitter AM, Segler A, Steiger K, et al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Sci Rep. 2017;7:41064.
   PubMed Web of Science ®Google Scholar
• Raphael BJ, Hruban RH, Aguirre AJ, et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185–203.e13.
   PubMed Web of Science ®Google Scholar
• Humphrey ES, Su S-P, Nagrial AM, et al. Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Mol Cell Proteomics. 2016;15:2671–2685.
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Duffy MJ, Hofmann BR, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56:e1–48.
   PubMed Web of Science ®Google Scholar
• Kim J, Bamlet WR, Oberg AL, et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017;9:eaah5583.
   PubMed Web of Science ®Google Scholar
• Harsha HC, Kandasamy K, Ranganathan P, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009;6:2–7.
   Web of Science ®Google Scholar
• Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2015;35:1–9.
   PubMed Web of Science ®Google Scholar
• Pantel K, Alix-Panabières C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 2013;73: 6384–6388.
   PubMed Web of Science ®Google Scholar
• Qi X, Yang X, Fan L, et al. Association between the spread of circulating tumor cells and breast cancer subtypes. Breast Cancer Res. 2010;12:402.
   PubMed Web of Science ®Google Scholar
• Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009;11:R59.
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Müller V, Loibl S, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin Cancer Res. 2017;23:5384–5393. clincanres.0255.2017.
   PubMed Web of Science ®Google Scholar
• Liu H, Sun B, Wang S, et al. Circulating tumor cells as a biomarker in pancreatic ductal adenocarcinoma. Cell Physiol Biochem. 2017;42:373–382.
   PubMed Web of Science ®Google Scholar
• Kulemann B, Rösch S, Seifert S, et al. Pancreatic cancer: circulating tumor cells and primary tumors show heterogeneous KRAS mutations. Sci Rep. 2017;7:4510.
   PubMed Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–6904.
   PubMed Web of Science ®Google Scholar
• Eason K, Sadanandam A. Molecular or metabolic reprograming: what triggers tumor subtypes? Cancer Res. 2016;76:5195–5200.
   PubMed Web of Science ®Google Scholar
• Daemen A, Peterson D, Sahu N, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci USA. 2015;112:E4410–E4417.
   PubMed Web of Science ®Google Scholar
• Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. [Internet]. 2011;9:77–87.
   PubMed Web of Science ®Google Scholar
• He L, Long LR, Antani S, et al. Histology image analysis for carcinoma detection and grading. Comput Methods Programs Biomed. 2012;107:538–556.
   PubMed Web of Science ®Google Scholar
• Knudsen E, Vail P, Balaji U, et al. Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunological markers. Clin Cancer Res. 2017;23:4429–4440. clincanres.0162.2017.
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–575.
   PubMed Web of Science ®Google Scholar
• Falasca M, Kim M, Casari I. Pancreatic cancer: current research and future directions. Biochim Biophys Acta - Rev Cancer. 2016;1865:123–132.
   PubMed Web of Science ®Google Scholar
• Vaccaro V, Sperduti I, Vari S, et al. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol. 2015;28:4788–4801.
   Google Scholar
• Philip PA, Mooney M, Jaffe D, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. JCO. 2009;27:5660–5669.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Agarwal B, Correa AM, Ho L. Survival in pancreatic carcinoma based on tumor size. Pancreas. 2008;36:e15–e20.
   PubMed Web of Science ®Google Scholar
• Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22.
   PubMed Web of Science ®Google Scholar
• Yeo TP, Lowenfels AB. Demographics and epidemiology of pancreatic cancer. Cancer J. 2012;18:477–484.
   PubMed Web of Science ®Google Scholar
• Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007;245:566–572.
   PubMed Web of Science ®Google Scholar
• Gerdes MJ, Sevinsky CJ, Sood A, et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci USA. 2013;110:11982–11987.
   PubMed Web of Science ®Google Scholar
• DeCant B, Principe DR, Guerra C, et al. Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. Front Physiol. 2014;5:1–12.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013.
   PubMed Web of Science ®Google Scholar
• Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652–4661.
   PubMed Web of Science ®Google Scholar
• Behrens D, Walther W, Fichtner I. Pancreatic cancer models for translational research. Pharmacol Ther. 2017;173:146–158.
   PubMed Web of Science ®Google Scholar
• Sahu RK, Mordechai S. Fourier transform infrared spectroscopy in cancer detection. Futur Oncol. 2005;1:635–647.
   PubMedGoogle Scholar
• Haka AS, Volynskaya Z, Gardecki J. A, et al. Diagnosing breast cancer using Raman spectroscopy: prospective analysis. J Biomed Opt. 2009;14:54023.
   Web of Science ®Google Scholar
• Lasch P, Haensch W, Naumann D, et al. Imaging of colorectal adenocarcinoma using FT-IR microspectroscopy and cluster analysis. Biochim Biophys Acta - Mol Basis Dis. 2004;1688:176–186.
   PubMed Web of Science ®Google Scholar
• Mackanos MA, Contag CH. Fiber-optic probes enable cancer detection with FTIR spectroscopy. Trends Biotechnol. 2010;28:317–323.
   PubMed Web of Science ®Google Scholar
• Roychowdhury S, Chinnaiyan AM. Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin. 2016;66:75–88.
   PubMed Web of Science ®Google Scholar